About Sirigen
Sirigen is a Healthcare company based in San Diego (United States) founded in 2003, and was acquired by Becton Dickinson in August 2012. High sensitivity fluorescence detection technologies for diagnostics and life science applications. Sirigen has raised $12.05 million across 3 funding rounds from investors including BD, Seraphim and YFM Equity Partners. Its chief executive, as recorded, is Nick Kerton. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Probes and Dyes. Its legal entity is SIRIGEN INC. Its competitors include Nanosphere, Marker Gene Technologies and Biotium; 1 of its 3 listed competitors has raised funding.
Company details
Sirigen was founded in 2003 in San Diego, United States, within the diagnostics and life sciences sector. High-sensitivity fluorescence detection technologies are created using a platform based on novel polymer chains to improve signal detection in assays. Products are supplied for applications including immunoassays, flow cytometry, proteomics, molecular diagnostics, microarrays, and imaging systems. Operations focus on enhancing traditional assay performance across these areas.
- Headquarters San Diego, United States
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website sirigen.com
- Social LinkedIn
- Acquired by Becton Dickinson (Aug 2012)
- Legal Name Sirigen Inc
- Total Equity Funding$12.05M (USD)
in 3 rounds
- Latest Funding Round$6.11M (USD), Series B
Oct 2010
- InvestorsBD
& 5 more
- Acquired byBecton Dickinson
(Aug 2012)
Funding Insights of Sirigen
Sirigen has successfully raised a total of $12.05M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $6.11 million completed in October 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $12.05M
- Total Rounds 3
- Last Round Series B — $6.11M
- First Round $3.96M
(Apr 2008)
- Investors Count 5
All 3 funding rounds of Sirigen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2010 | $6.11M | Series B | – | YFM Equity Partners, IQ Capital | |
| May 2009 | $1.98M | Series A | – | Oxford Capital, Seraphim | – |
| Apr 2008 | $3.96M | Series A | – | Seraphim, Oxford Capital | – |
6 investors in total: 6 institutional.
Investors in Sirigen
Sirigen has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include BD, Seraphim and YFM Equity Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage space-tech startups are invested in by Seraphim. | 2006 | seraphim.vc | London, United Kingdom | |
Early-stage venture capital is invested in UK technology sectors. | oxcp.com | Oxford, United Kingdom | ||
Private equity firm focused on multiple sectors | 1982 | yfmep.com | Leeds, United Kingdom | |
Deep tech venture capital firm investing in European and global startups. | iqcapital.vc | |||
Impact investments are made in mission-led technology ventures. | nestainvestments.org.uk | London, United Kingdom | ||
BD is recognized for providing innovative medical technology solutions. | 1897 | bd.com | Franklin Lakes, United States |
Investor details for Sirigen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Sirigen
1 people are tracked at Sirigen (1 in leadership).
| Name | Role | Group |
|---|---|---|
Nick Kerton | CEO | Leadership |
Complete people profiles for Sirigen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Sirigen
4 dated milestones of Sirigen across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Sirigen is founded.
- Funding First funding round of $4.0M.
- Funding Latest funding round, Series B, of $6.1M.
- Exit Acquired by Becton Dickinson.
Competitors of Sirigen
Sirigen has 3 listed competitors in our database, 1 of them funded. They include Nanosphere, Marker Gene Technologies and Biotium.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| nanosphere.us | 1999 | Northbrook, United States | $97.75M | 146 | Diagnostic tests for personalized medicine targeting infections are provided. | |
| markergene.com | 1993 | Eugene, United States | Develops kits and reagents for research application | |||
| biotium.com | 2001 | Hayward, United States | 27 | Provides fluorescent products for PCR, DNA analysis, and cell staining in research. |
Detailed competitors of Sirigen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Sirigen (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sirigen
Complete news archive for Sirigen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sirigen
Sirigen was founded in 2003 and raised its 1st funding round 5 years after it was founded.
Sirigen is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Nick Kerton is the CEO of Sirigen, as recorded in our data.
Sirigen is a funded company, having raised a total of $12.05M across 3 funding rounds to date. The company's 1st funding round was a Series A of $3.96M, raised on Apr 2008.
Sirigen was founded in 2003 in San Diego, United States, within the diagnostics and life sciences sector. High-sensitivity fluorescence detection technologies are created using a platform based on novel polymer chains to improve signal detection in assays. Products are supplied for applications including immunoassays, flow cytometry, proteomics, molecular diagnostics, microarrays, and imaging systems. Operations focus on enhancing traditional assay performance across these areas.
Sirigen's top competitors include Nanosphere, Marker Gene Technologies and Biotium.
Sirigen has 6 investors. Key investors include BD, Seraphim, YFM Equity Partners, Oxford Capital, and IQ Capital.
Sirigen operates through Sirigen Inc.
Yes. Sirigen was acquired by Becton Dickinson in August 2012.